Quarterly report pursuant to Section 13 or 15(d)

CONCENTRATIONS

v3.10.0.1
CONCENTRATIONS
9 Months Ended
Sep. 30, 2018
Notes to Financial Statements  
NOTE 15 - CONCENTRATIONS

Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit.

 

The Company’s revenues earned from sale of products and services for the three months ended September 30, 2018 included 24%, 11%, 27% and 26% (aggregate of 88%) from four customers of the Company’s total revenues.

 

The Company’s revenues earned from sale of products and services for the nine months ended September 30, 2018 included 20%, 21%, 20% and 18% (aggregate of 79%) from four customers of the Company’s total revenues.

 

The Company's revenues earned from sale of products and services for the three months ended September 30, 2017 included 21% from one customer of the Company's total revenues.

 

The Company did not have a concentration for the nine months ended September 30, 2017.

 

Four customers accounted for 47%, 18%, 18% and 17% (aggregate of 100%) of the Company’s total accounts receivable at September 30, 2018 and three customers accounted for 12%, 19% and 13% (aggregate of 44%) of the Company’s total accounts receivable at December 31, 2017.

 

The Company relies on Trinity Rx as its sole supplier of its Naltrexone implant.